Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 434,478 Shares
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 434,478 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the sale, the chief operating officer now owns 1,127,290 shares of the company's stock, valued at $12,197,277.80. This trade represents a 27.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Eric Venker also recently made the following trade(s):
Shares of ROIV stock traded up $0.04 on Monday, hitting $10.83. 6,976,198 shares of the company's stock were exchanged, compared to its average volume of 5,636,264. The company has a 50 day moving average of $10.78 and a 200 day moving average of $11.46. The stock has a market cap of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.93 and a 12 month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Natixis Advisors LLC grew its position in Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company's stock worth $1,774,000 after acquiring an additional 11,726 shares during the last quarter. Swiss National Bank grew its holdings in shares of Roivant Sciences by 1.0% during the third quarter. Swiss National Bank now owns 721,046 shares of the company's stock worth $8,321,000 after purchasing an additional 6,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Roivant Sciences by 30.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company's stock valued at $31,936,000 after buying an additional 646,627 shares during the period. Loomis Sayles & Co. L P raised its holdings in Roivant Sciences by 13.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after buying an additional 458,601 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Roivant Sciences by 10.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company's stock worth $4,115,000 after buying an additional 34,641 shares during the period. Institutional investors own 64.76% of the company's stock.
Several analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has an average rating of "Buy" and a consensus target price of $18.08.
Read Our Latest Report on ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
